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Mutations in PUS3, which encodes a highly conserved enzyme responsible for post-
transcriptional modiﬁcation of tRNA, have been shown in a single family to be a cause of
nonsyndromic intellectual disability (ID).1 In this study, we used whole-exome sequencing
(WES) to identify biallelic mutations in PUS3 associated with syndromic ID with dysmorphic
features, white matter disease (WMD), and renal abnormalities in a nonconsanguineous family
from Brazil.
Clinical ﬁndings
We evaluated 2 sisters (ﬁgure, A) who had ID, renal abnormalities, diﬀuse WMD, and dys-
morphic features. Their brother was similarly aﬀected and died at age 22 years of complications
of renal disease. The parents were nonconsanguineous from Northeast Brazil and Southern
Italy. We obtained approval from the institutional ethics committee and written informed
consent from family members.
The ﬁrst patient (P1; III-3; ﬁgure, A) was noted to have global developmental delay after age
1 year. As a child, she could understand short sentences, but expressive language was limited
to monosyllables. She was diagnosed with profound ID but was independent in basic activities
of daily living (ADLs). She had 2 focal dyscognitive seizures with secondary generalization, at
age 18 and 23 years, responsive to carbamazepine. At age 37 years, asymptomatic proteinuria
and reduced creatinine clearance were detected. At 44 years, she developed psychosis, with
prominent auditory and visual hallucinations and episodes of aggression. Physical examina-
tion revealed her to be on the 10th centile for height, weight, and head circumference and to
have genu valgum. In addition, neurologic examination revealed dysarthria, pseudobulbar
aﬀect, with impaired gait and balance.
The second patient (P2; III-6; ﬁgure, A) also presented with short stature, neurodevelopmental
delay, and dysmorphic features. She was diagnosed with acute nephritis at age 6 months and
coeliac disease at age 5 years. She also developed generalized phenobarbital responsive seizures.
She was able to walk and could complete ADLs with assistance. At age 20 years, she developed
nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) with mesangial granular
deposits and positive IgM and C3 immunoﬂuorescence. She did not respond to steroids
and developed end-stage renal failure requiring hemodialysis. Physical examination revealed
that she was on the 3rd centile for height, weight, and head circumference and to have gray
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sclera, genu valgum, pseudobulbar aﬀect, and dysarthria. She
died at age 40 years of complications of community-acquired
pneumonia.
Neuroimaging findings
MRI identiﬁed white matter abnormalities in both patients. In
P1, there were scattered T2/ﬂuid-attenuated inversion recovery
(FLAIR) hyperintensities in the cerebral white matter, more
prominent in periventricular zones (ﬁgure, D). In P2, there was
symmetric diﬀuse T2/FLAIR hyperintensity in the cerebral and
cerebellar white matter with extension to the subcortical areas,
mild T2 hyperintensity in the globus pallidus bilaterally, and
signs of brain parenchymal volume loss (ﬁgure, E–G). There
was no gadolinium enhancement or areas of restricted diﬀusion.
Genetic findings
We performedWES on both patients and ﬁltered the data for
a presumed autosomal recessive inheritance pattern. There
were no regions of homozygosity and no shared rare ho-
mozygous variants. However, when ﬁltered for damaging,
rare compound heterozygous mutations, we identiﬁed bial-
lelic mutations only in PUS3 (p.Arg166Gln;p.Leu366Pro)
Figure Genetic and radiologic findings
(A) Family pedigree: 2 affected individuals were compound heterozygotes for p.Arg166Gln and p.Leu366Pro PUS3 mutations, whereas their healthy
mother and sister were heterozygotes for only 1 of the mutations. (B) Sanger sequencing electropherograms showing both c.497G>A (p.Arg166Gln)
and c.1097T>C (p.Leu366Pro) PUS3 mutations. (C) Vertebrate protein sequencing alignment showing conserved amino acid sites for both PUS3
mutations. (D) Scattered FLAIR hyperintensities in the cerebral white matter in P1. (E) Symmetric diffuse FLAIR hyperintensity in the cerebral white
matter in P2. (F) Axial T2-weighted image discloses not only the white matter changes in P2 but also mild T2 hyperintensity in the globus pallidus
bilaterally (arrows). One can notice also in P2 symmetric FLAIR hyperintensities in the cerebellar white matter (arrows in G), together with signs of brain
parenchyma volume loss (E–G).
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(ﬁgure, B). Both are very rare and highly conserved residues
among vertebrates. We conﬁrmed the mutations by Sanger
sequencing and demonstrated that they were inherited in
trans.
Discussion
PUS3 codes for pseudourydilate synthase, a highly conserved
enzyme responsible for posttranscriptional modiﬁcation of
tRNA,2 which is critical for its structure, function, and sta-
bility. Most of these modiﬁcations have been recently recog-
nized in a growing number of human genes leading to
ID–FTSJ1, TRMT1, NSUN2, WDR4, ADAT3, and PUS3.3
The original report of PUS3-related disorder describes a family
with 3 aﬀected individuals (age: 3–15 years) from Saudi Arabia
with severe ID, multifocal white matter changes, and in a single
patient, epilepsy. No nephropathy was reported. WES detected
a homozygous truncatingmutation (p.Arg435Ter), predicting to
lead to a loss of function. In our patients, aﬀected individuals have
a milder intellectual compromise and developed proteinuria/
nephrotic syndrome after age 20 years. In addition, the white
matter abnormalities were more extensive in our patients.
Of interest, a well-known mechanism of WMD is disruption
of protein translation as is seen in mutations in mitochondrial
aspartate (DARS2) or glutamate (EARS2) transfer-RNA
synthase. It is also noteworthy that leukoencephalopathies
usually cause progressive neurologic deterioration and not
static encephalopathy with ID, as occurred in our patients.
The late-onset renal involvement observed in our patients
expands the phenotype of PUS3-related disorder. Steroid-
resistant FSGS has been rarely associated with mutations in
mitochondrial tRNA in patients with other features typical of
mitochondrial dysfunction.4–7 Recently, tubulopathy was
reported in deﬁciency of tRNA N6-adenosine threonylcarba-
moyltransferase, an enzyme involved in posttranscriptional
tRNA modiﬁcation.
This study expands the known phenotypic and allelic spec-
trum of PUS3-related disorder. In addition, it provides further
evidence of the relevance of posttranscriptional modiﬁcation
of tRNA in neurologic diseases. Given these additional ﬁnd-
ings, we believe the phenotypic spectrum of PUS3 mutations
to be wider than the initial report.
Acknowledgment
The authors thank the patients and their family for participating
in this study.
Study funding
No targeted funding reported.
Disclosure
A.R.B. de Paiva, D.S. Lynch, andU.S.Melo report no disclosures.
L.T. Lucato has received speaker honoraria fromBracco Imaging
Appendix 1. Author contributions
Name Location Role Contribution
Anderson
Rodrigues
Brandão de
Paiva, MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Study concept
and design,
acquisition of
data, and writing
the manuscript.
David S.
Lynch, MD,
PhD
UCL Institute of
Neurology, London,
United Kingdom
Author Study concept
and design,
acquisition of
data, and writing
the manuscript.
Uira´ Souto
Melo, PhD
Human Genome and
Stem Cell Research
Center, Department of
Genetics and
Evolutionary Biology,
Instituto de Biocieˆncias,
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Leandro
Tavares
Lucato, MD,
PhD
Neuroradiology
Section, Hospital das
Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Fernando
Freua, MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Bruno Della
Ripa de Assis,
MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Isabella
Barcelos, MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Clarice Listik,
MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Diego de
Castro dos
Santos, MD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas da
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Lu´cia Ineˆs
Macedo-
Souza, PhD
Human Genome and
Stem Cell Research
Center, Department
of Genetics and
Evolutionary Biology,
Instituto de Biocieˆncias,
Universidade de São
Paulo, São Paulo, Brazil
Author Acquisition of
data and critical
revision of the
manuscript.
Henry
Houlden, MD,
PhD
UCL Institute of
Neurology, London,
United Kingdom
Author Critical revision of
the manuscript
Fernando
Kok, MD, PhD
Neurogenetics Unit,
Neurology Department,
Hospital das Cl´ınicas
da Universidade de
São Paulo, São Paulo,
Brazil
Author Critical revision of
the manuscript
Neurology.org/NG Neurology: Genetics | Volume 5, Number 1 | February 2019 3
do Brasil and has served on the editorial board of Arquivos de
Neuro-Psiquiatria. F. Freua, B.D.R. de Assis, I. Barcelos, C. Listik,
D. Castro Santos, and L.I. Macedo-Souza report no disclosures.
H. Houlden has received governmental and/or foundation/
society support from the Medical Research Council (MRC)
UK, the BRT, the MDA USA, Muscular Dystrophy UK,
Ataxia UK, Muscular Dystrophy UK, Rosetrees Trust, the
Wellcome Trust, and the National Institute for Health Re-
search (NIHR) UCL/UCLH BRC. F. Kok has served on the
editorial board of Arquivos de Neuro-Psiquiatria; holds a
patent for methylmalonic acid determination by tandemmass
spectrometry using stable isotope; is employed as Medical
Director for Mendelics Genomic Analysis; has acted as
a speaker for Actelion Pharmaceuticals at the NPC symposia
and for BioMarin Pharmaceuticals at the CLN2 symposia;
and has been a shareholder of Mendelics Genomic Analysis.
Full disclosure form information provided by the authors is
available with the full text of this article at Neurology.org/NG.
Publication history
Received byNeurology: Genetics August 13, 2018. Accepted in ﬁnal form
November 8, 2018.
References
1. Shaheen R, Han L, Faqeih E, et al. A homozygous truncating mutation in PUS3 expands
the role of tRNA modiﬁcation in normal cognition. Hum Genet 2016;135:707–713.
2. Hur S, Stroud RM. How U38, 39, and 40 of many tRNAs become the targets for
pseudouridylation by TruA. Mol Cell 2007;26:189–203.
3. Torres AG, Batlle E, Ribas de Pouplana L. Role of tRNA modiﬁcations in human
diseases. Trends Mol Med 2014;20:306–314.
4. Dinour D, Mini S, Polak-Charcon S, Lotan D, Holtzman EJ. Progressive ne-
phropathy associated with mitochondrial tRNA gene mutation. Clin Nephron
2004;62:149–154.
5. Scaglia F1, Vogel H, Hawkins EP, Vladutiu GD, Liu LL,Wong LJ. Novel homoplasmic
mutation in the mitochondrial tRNATyr gene associated with atypical mitochondrial
cytopathy presenting with focal segmental glomerulosclerosis. Am J Med Genet A
2003;123A:172–178.
6. Gue´ry B, Choukroun G, Noe¨l LH, et al. The spectrum of systemic involvement in
adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation.
J Am Soc Nephrol 2003;14:2099–2108.
7. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and
pathologic features of focal segmental glomerulosclerosis with mitochondrial
tRNALeu(UUR) gene mutation. Kidney Int 2001;59:1236–1243.
4 Neurology: Genetics | Volume 5, Number 1 | February 2019 Neurology.org/NG
DOI 10.1212/NXG.0000000000000306
2019;5; Neurol Genet 
Anderson Rodrigues Brandão de Paiva, David S. Lynch, Uirá Souto Melo, et al. 
nephropathy
 mutations are associated with intellectual disability, leukoencephalopathy, andPUS3
This information is current as of January 16, 2019
Services
Updated Information &
 http://ng.neurology.org/content/5/1/e306.full.html
including high resolution figures, can be found at:
References
 http://ng.neurology.org/content/5/1/e306.full.html##ref-list-1
This article cites 7 articles, 1 of which you can access for free at: 
Subspecialty Collections
 http://ng.neurology.org//cgi/collection/mental_retardation
Mental retardation
 http://ng.neurology.org//cgi/collection/leukodystrophies
Leukodystrophies
 http://ng.neurology.org//cgi/collection/all_genetics
All Genetics
following collection(s): 
This article, along with others on similar topics, appears in the
  
Permissions & Licensing
 http://ng.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://ng.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
reserved. Online ISSN: 2376-7839.
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
an open-access, online-only, continuous publication journal. Copyright Copyright © 2019 The Author(s). 
is an official journal of the American Academy of Neurology. Published since April 2015, it isNeurol Genet 
